CSI Market
Sign In | Register

Pacific Biosciences Of California Inc (PACB) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PACB quarterly Cash Flow →
A period-by-period view of cash flow from Pacific Biosciences Of California Inc to Dec 31 2021 helps clarify how Dec 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-546.38
Depreciation & amortization12.99
Amortization of Other Assets369.45
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability-18.70
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase8.15
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation41.67
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Increase Decrease In Deferred Service Revenue-
Investment Income Net Amortization Of Discount And Premium-4.37
Operating Lease Right Of Use Asset Amortization-
Finance Lease Right Of Use Asset Amortization-
Gain Loss On Termination Of Lease-
Inventory Transferred To From Property And Equipment-
Increase Decrease In Contract With Customer Asset-
Operating Lease Payments-
Operating Lease Right Of Use Asset Amortization Expense3.98
Increase Decrease In Contract With Customer Liability0.10
Noncash Merger Related Costs-
Increase Decrease In Contingent Consideration Liability-
Increase Decrease In Operating Lease Liability-
Increase Decrease In Contingent Consideration Liability-
Income taxes-0.55
Gain (Loss) on Sale of Derivatives0.00
Increase (Decrease) in Accounts Receivable-7.92
Increase (Decrease) in Accounts Payable2.48
Increase (Decrease) in Accrued Liabilities3.16
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets8.51
Other Working Capital-1.19
Other Noncash Income (Expense)1.69
Other net0.00
Payments for (Proceeds from) Other Operating Activities15.72
Discontinued operations0.00
Net Cash flow from Operating Activities-111.21
Investing Activities
Capital Expenditures-7.71
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities340.07
Short-term Investments Acq.0.00
Real Estate Investments0.00
Stock Issued-
Stock Issued-
Stock Issued-
Stock Issued-
Payment For Waiver Of Milestone Obligation-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-216.91
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities115.45
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock3.43
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-57.59
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents57.59
Proceeds From Contract Termination-
Proceeds From Repayments Of Contract Termination-
Proceeds From Issuance Of Common Stock Under Equity Offerings Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities3.43
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-118.92
Total Cash Flow7.67
4 historic quarters locked

Sign in to unlock the full Pacific Biosciences Of California Inc cash flow history.

Sign In Create Free Account

About Pacific Biosciences Of California Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 25, 2026
  • Source: pacb-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001299130-26-000034

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License